GB9809556D0 - Pharmaceutical formulation comprising a 5-HT agonist in combination with an antiemetic and/or gastroprokinetic agent - Google Patents

Pharmaceutical formulation comprising a 5-HT agonist in combination with an antiemetic and/or gastroprokinetic agent

Info

Publication number
GB9809556D0
GB9809556D0 GBGB9809556.5A GB9809556A GB9809556D0 GB 9809556 D0 GB9809556 D0 GB 9809556D0 GB 9809556 A GB9809556 A GB 9809556A GB 9809556 D0 GB9809556 D0 GB 9809556D0
Authority
GB
United Kingdom
Prior art keywords
antiemetic
agonist
combination
pharmaceutical formulation
gastroprokinetic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB9809556.5A
Other versions
GB2325161A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Publication of GB9809556D0 publication Critical patent/GB9809556D0/en
Publication of GB2325161A publication Critical patent/GB2325161A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
GB9809556A 1997-05-14 1998-05-05 Pharmaceutical formulation comprising a 5-HT agonist and an anti-emetic and/or gasto-prokinetic agent Withdrawn GB2325161A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9709739.8A GB9709739D0 (en) 1997-05-14 1997-05-14 Pharmaceutical formulation

Publications (2)

Publication Number Publication Date
GB9809556D0 true GB9809556D0 (en) 1998-07-01
GB2325161A GB2325161A (en) 1998-11-18

Family

ID=10812266

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB9709739.8A Pending GB9709739D0 (en) 1997-05-14 1997-05-14 Pharmaceutical formulation
GB9809556A Withdrawn GB2325161A (en) 1997-05-14 1998-05-05 Pharmaceutical formulation comprising a 5-HT agonist and an anti-emetic and/or gasto-prokinetic agent

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB9709739.8A Pending GB9709739D0 (en) 1997-05-14 1997-05-14 Pharmaceutical formulation

Country Status (1)

Country Link
GB (2) GB9709739D0 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255334B1 (en) * 1998-10-30 2001-07-03 Pfizer Inc 5HT 1 receptor agonists and metoclopramide for the treatment of migraine
GB0002312D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
GB0002336D0 (en) 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
GB0105131D0 (en) * 2001-03-01 2001-04-18 Pfizer Ltd Compositions having improved bioavailability
JP5714910B2 (en) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ，インコーポレイテッド Pharmaceutical composition
AU2013202680C1 (en) * 2008-04-28 2016-06-23 Zogenix, Inc. Novel formulations for treatment of migraine
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US10179109B2 (en) 2016-03-04 2019-01-15 Charleston Laboratories, Inc. Pharmaceutical compositions comprising 5HT receptor agonist and antiemetic particulates

Also Published As

Publication number Publication date
GB9709739D0 (en) 1997-07-02
GB2325161A (en) 1998-11-18

Similar Documents

Publication Publication Date Title
HUP0203028A3 (en) Pharmaceutical formulation containing tolterodine and its use
HUP0102658A3 (en) Pharmaceutical composition containing opioid agonist and antagonist combination
HK1112180A1 (en) Pharmaceutical use and compositions involving isoflavones
EP0885199A4 (en) Kappa agonist compounds and pharmaceutical formulations thereof
AU3572599A (en) Analgesic compositions comprising nmda-antagonists and abt-594
AU6983998A (en) Substituted carboxylic acylating agent compositions and derivatives thereof for use in lubricants and fuels
HUP9700588A3 (en) Pharmaceutical composition containing amlodipin as active component and kit for diminishing morbidity and/or mortality
AP9901623A0 (en) Pharmaceutical formulations comprising amoxocyllin and clavulanate
AU5783898A (en) Active delivery device and related procedures
HK1033653A1 (en) Synergistic composition and use thereof
IL145715A0 (en) Formulation arrays and use thereof
HUP0103636A3 (en) 2-methyl-thieno-benzodiazepine formulation and its use
ZA9810272B (en) Formulation of a cobination of a opioid and a alpha-adrenergic agonist and the use thereof
KR970009885B1 (en) 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammtory agent
GB9809556D0 (en) Pharmaceutical formulation comprising a 5-HT agonist in combination with an antiemetic and/or gastroprokinetic agent
HUP0003189A3 (en) Pharmaceutical composition comprising fexofenadine and its derivatives
IL140742A0 (en) Raloxifene and pharmaceutical composition comprising the same
ZA9811346B (en) Substituted heterocyclic benzocycloalkenes and their use as an analgesic
EP0922740A4 (en) Gelling agent and gel compositions
AU1510200A (en) Composition containing an analgesic and a xanthine or a xanthine derivative
ZA982952B (en) Pseudo-peptide compounds their preparation and use in pharmaceutical formulations
HUP9901792A3 (en) An aqueous formulation comprising bambuterol and the use thereof
GB2336582B (en) Improvements in storage and display devices
AU7681498A (en) Pharmaceutical composition and use thereof
ZA981782B (en) The use of levobupivacaine in combination with other drugs

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)